# Contact Wolverine Buy: BPC-157 TB-500 Editorial Record

> Contact Wolverine Buy, an independent editorial digest of BPC-157 TB-500 research. Editorial correspondence only — not a clinic, not a vendor, and not a source for the compounds.

For corrections, source suggestions, and editorial questions about the BPC-157 TB-500 digest.

## Editorial correspondence

This is the contact surface for the **BPC-157 TB-500** editorial record. We welcome corrections, additional peer-reviewed sources we may have missed, and questions about how a particular finding is summarized. If you believe a citation is misread or a regulatory detail is out of date, tell us and point to the source — accuracy of the record is the whole point of the project.

What we cannot help with: we are not a clinic and do not give medical advice, we do not manufacture or sell either peptide, and we cannot direct anyone to a place to obtain the blend or its constituents. Messages asking where to buy, how to dose for personal use, or how to obtain a restricted substance outside the lawful framework will not receive that information.

## Send a note

Use the form below to reach the editors. Include a link to any study or document you are referencing so we can verify it against the record. We read every note, though we cannot promise an individual reply to each one.

General information on this site describes the regulatory landscape and the published research; it is not medical or legal advice, and nothing here is an offer to sell or supply any substance.

---

Two complementary repair signals carved as two mirrored glyph-channels — BPC-157 read against its studies on one side, TB-500 against its own on the other, the join between them left uncarved because no combination trial exists, and the FDA 503A and WADA record set in the margin; no clinic behind the tablet and nothing here dispensed.